Bioceres Crop Solutions Future Growth
Future criteria checks 4/6
Bioceres Crop Solutions is forecast to grow earnings and revenue by 37.9% and 18.3% per annum respectively. EPS is expected to grow by 37.6% per annum. Return on equity is forecast to be 12.5% in 3 years.
Key information
37.9%
Earnings growth rate
37.6%
EPS growth rate
Chemicals earnings growth | 17.8% |
Revenue growth rate | 18.3% |
Future return on equity | 12.5% |
Analyst coverage | Low |
Last updated | 28 Aug 2024 |
Recent future growth updates
Recent updates
These 4 Measures Indicate That Bioceres Crop Solutions (NASDAQ:BIOX) Is Using Debt Extensively
Aug 03Bioceres Needs To Add Clarity Around Borrowings
Mar 23Bioceres Crop Solutions (NASDAQ:BIOX) Takes On Some Risk With Its Use Of Debt
Feb 03Does Bioceres Crop Solutions (NASDAQ:BIOX) Have A Healthy Balance Sheet?
Oct 04Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Popularity With Investors Is Clear
Jun 21Here's Why Bioceres Crop Solutions (NASDAQ:BIOX) Is Weighed Down By Its Debt Load
May 09Bioceres: A Resilient Small Cap With Conference Appearances After Thursday's Earnings
Sep 06Bioceres Crop Solutions jumps 15% after investor pitch
Aug 23We Think Bioceres Crop Solutions (NASDAQ:BIOX) Is Taking Some Risk With Its Debt
Apr 10Bioceres Has Not Resolved Its Major Risks And Is Growing Based On Commodities Bullishness
Mar 31Is Now The Time To Look At Buying Bioceres Crop Solutions Corp. (NASDAQ:BIOX)?
Mar 17Is Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Trading At A 21% Discount?
Nov 13Bioceres Crop Solutions (NASDAQ:BIOX) Shareholders Will Want The ROCE Trajectory To Continue
Jul 08Estimating The Intrinsic Value Of Bioceres Crop Solutions Corp. (NASDAQ:BIOX)
Jun 16What Does Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Share Price Indicate?
May 26Bioceres partners with Havanna to offer consumers HB4 wheat-based sustainable products
May 10Does Bioceres Crop Solutions (NASDAQ:BIOX) Have A Healthy Balance Sheet?
May 05Bioceres Crop Solutions (NYSEMKT:BIOX) Shareholders Will Want The ROCE Trajectory To Continue
Apr 05Are Investors Undervaluing Bioceres Crop Solutions Corp. (NYSEMKT:BIOX) By 22%?
Mar 10Bioceres Crop Solutions (NYSEMKT:BIOX) Shareholders Booked A 53% Gain In The Last Year
Feb 12Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2027 | 930 | 136 | N/A | 102 | 1 |
6/30/2026 | 673 | 93 | 81 | 86 | 3 |
6/30/2025 | 565 | 61 | 75 | 80 | 5 |
6/30/2024 | 471 | 19 | 25 | 36 | 4 |
3/31/2024 | 446 | 3 | -13 | 10 | N/A |
12/31/2023 | 455 | 22 | 6 | 30 | N/A |
9/30/2023 | 409 | 14 | 26 | 50 | N/A |
6/30/2023 | 419 | 19 | -20 | 3 | N/A |
3/31/2023 | 416 | 15 | -12 | 6 | N/A |
12/31/2022 | 391 | -19 | -3 | 11 | N/A |
9/30/2022 | 389 | -8 | -47 | -36 | N/A |
6/30/2022 | 328 | -7 | -27 | -18 | N/A |
3/31/2022 | 308 | -2 | -1 | 9 | N/A |
12/31/2021 | 275 | 4 | -12 | -2 | N/A |
9/30/2021 | 231 | 1 | -27 | -12 | N/A |
6/30/2021 | 207 | -7 | -20 | -6 | N/A |
3/31/2021 | 174 | -5 | -36 | -24 | N/A |
12/31/2020 | 164 | -7 | -24 | -13 | N/A |
9/30/2020 | 178 | 3 | -9 | -4 | N/A |
6/30/2020 | 172 | 3 | 5 | 9 | N/A |
3/31/2020 | 174 | 0 | 14 | 18 | N/A |
12/31/2019 | 167 | -18 | 28 | 32 | N/A |
9/30/2019 | 167 | -23 | 18 | 22 | N/A |
6/30/2019 | 160 | -18 | 26 | 30 | N/A |
3/31/2019 | 142 | -26 | 29 | 33 | N/A |
12/31/2018 | 145 | -8 | 22 | 27 | N/A |
9/30/2018 | 129 | -13 | 31 | 37 | N/A |
6/30/2018 | 133 | -11 | 13 | 18 | N/A |
6/30/2017 | 94 | -12 | N/A | 19 | N/A |
12/31/2016 | 41 | -6 | N/A | -1 | N/A |
12/31/2015 | 5 | -1 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIOX's forecast earnings growth (37.9% per year) is above the savings rate (2.5%).
Earnings vs Market: BIOX's earnings (37.9% per year) are forecast to grow faster than the US market (15.2% per year).
High Growth Earnings: BIOX's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: BIOX's revenue (18.3% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: BIOX's revenue (18.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BIOX's Return on Equity is forecast to be low in 3 years time (12.5%).